Profile data is unavailable for this security.
About the company
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
- Revenue in CHF (TTM)8.96m
- Net income in CHF-16.04m
- Incorporated2002
- Employees23.00
- LocationNewron Pharmaceuticals SpAvia Antonio Meucci 3BRESSO 20091ItalyITA
- Phone+39 26103461
- Fax+39 261034654
- Websitehttps://www.newron.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Santhera Pharmaceuticals Holding AG | 103.38m | 54.78m | 117.03m | 46.00 | -- | 1.73 | -- | 1.13 | -17.28 | -17.28 | 9.14 | 5.34 | 1.19 | 3.37 | 63.69 | -- | 63.20 | -33.83 | 136.70 | -52.56 | 96.87 | 86.74 | 52.99 | -79.40 | 0.75 | 3.57 | 0.2628 | -- | 1,283.33 | 26.70 | 177.08 | -- | 1.87 | -- |
| Molecular Partners AG | 6.73m | -58.53m | 124.54m | 168.00 | -- | 0.6621 | -- | 18.52 | -1.78 | -1.78 | 0.2043 | 5.13 | -- | -- | -- | 40,035.71 | -- | -11.83 | -- | -14.69 | -- | 99.28 | -870.22 | -45.30 | -- | -- | 0.0195 | -- | -96.29 | -7.43 | -152.59 | -- | -1.40 | -- |
| Newron Pharmaceuticals SpA | 8.96m | -16.04m | 187.93m | 23.00 | -- | -- | -- | 20.98 | -0.8991 | -0.8991 | 0.5019 | -1.66 | 0.2873 | -- | 4.57 | 389,414.50 | -51.45 | -37.10 | -111.53 | -43.98 | 94.80 | 91.72 | -179.13 | -270.48 | -- | -2.86 | 2.62 | -- | 48.62 | 17.61 | 7.25 | -- | -22.76 | -- |
| Xlife Sciences AG | 988.44k | 14.88m | 194.48m | 17.00 | 28.00 | 0.7111 | 7.69 | 196.76 | 1.22 | 1.22 | 0.1382 | 47.95 | 0.002 | -- | 0.2044 | 58,143.53 | 1.85 | -- | 2.33 | -- | 45.43 | -- | 938.17 | -- | -- | -- | 0.1345 | -- | -3.85 | -- | 3.96 | -- | -- | -- |
| Kuros Biosciences AG | 33.56m | -13.73m | 287.99m | 80.00 | -- | 5.06 | -- | 8.58 | -0.3697 | -0.3697 | 0.9175 | 1.54 | 0.4347 | 2.40 | 7.27 | 419,550.00 | -17.78 | -13.47 | -21.34 | -14.84 | 71.31 | 78.73 | -40.90 | -81.48 | 1.69 | -84.04 | 0.0364 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
| Idorsia Ltd | 141.42m | -55.88m | 411.19m | 938.00 | -- | -- | -- | 2.91 | -0.3534 | -0.3534 | 0.7363 | -4.97 | 0.1912 | 0.1645 | 113.09 | 150,766.50 | -7.56 | -46.72 | -12.46 | -53.84 | 93.05 | -- | -39.51 | -709.80 | 1.00 | -26.26 | 5.82 | -- | 56.93 | 20.25 | 64.01 | -- | -8.01 | -- |
| Basilea Pharmaceutica AG Allschwil | 157.63m | 10.45m | 567.62m | 147.00 | 49.18 | -- | 47.10 | 3.60 | 0.8765 | 0.8765 | 13.15 | -0.8335 | 0.7999 | 1.06 | 5.16 | 1,072,340.00 | 5.30 | -1.86 | 7.69 | -2.99 | 83.00 | 83.45 | 6.63 | -2.99 | 2.64 | 2.02 | 1.10 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
Data as of May 22 2024. Currency figures normalised to Newron Pharmaceuticals SpA's reporting currency: Swiss Franc CHF
8.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Heights Capital Management, Inc.as of 14 Mar 2024 | 750.00k | 4.03% |
| Z�rcher Kantonalbank (Investment Management)as of 28 Mar 2024 | 225.18k | 1.21% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 216.39k | 1.16% |
| UBS Asset Management Switzerland AGas of 07 May 2024 | 153.11k | 0.82% |
| Pictet Asset Management SAas of 31 Jan 2024 | 48.43k | 0.26% |
| BlackRock Asset Management Schweiz AGas of 08 May 2024 | 42.25k | 0.23% |
| Credit Suisse AGas of 31 Jan 2024 | 24.67k | 0.13% |
| DWS CH AGas of 28 Mar 2024 | 17.13k | 0.09% |
| Baloise Asset Management AGas of 28 Mar 2024 | 16.86k | 0.09% |
| Lombard Odier Asset Management (Switzerland) SAas of 29 Mar 2024 | 10.83k | 0.06% |
More ▼
Data from 28 Mar 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
